FDA scolds Sun Pharma for allegedly backdating documents; Axsome’s fast-acting depression treatment approved

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     STAT+: FDA scolds Sun Pharma for allegedly backdating documents and fudging records for collecting drug samples By Ed Silverman Jacquelyn Martin/AP Sun Pharma allegedly falsified various documents that were maintained by employees at one of its plants in India, according to the FDA. Read More STAT+: FDA approves Axsome's fast-acting treatment for major depression By Damian Garde Adobe Auvelity is a combination of dextromethorphan, commonly found in cough suppressants, and a generic form of Wellbutrin. Read More Opinion: The Inflation Reduction Act: One step closer to pharmacoequity? By Utibe R. Essien MANDEL NGAN/ Getty One overlooked benefit of the Inflation Reduction Act may be the law's role in reducing health disparities. Read More Sponsor content by Salesforce STAT E-Book: How technology shapes patient experiences Our latest e-book underscores the vast range of technologies that are shaping how patients find and receive health care, from smartphone apps to deliver therapy and bedside bots to channel medication requests to new tools to collect real-world data and wearable watches to detect heart health. These stories illustrate the exciting advances being made on these technologies and highlight the challenges to their broader adoption. Download now. 'A poster child' for diversity in science: Black engineers work to fix long-ignored bias in oxygen readings By Usha Lee McFarling Courtesy Joshua Burrow "I said, 'Wait a minute, it's an approved device and no one looked at this?'" one engineer said when told about pulse oximeters' bias. Read More STAT+: Up and down the ladder: The latest comings and goings By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More Friday, August 19, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser